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Abstract
We report a case of a patient with Chronic Eosinophilic Leukemia (CEL) 
with mutation in alfa PDGFR gene exhibiting a satisfactory response 
to treatment with imatinib mesylate. A 25-year-old man presented in 
a hematology service with a persistent cough and hemogram altera-
tions. His blood count showed a hemoglobin level of 12.5 g/dL and a 
white blood cell count of 94,030/mm3, eosinophils were 68% of all 
cells. Bone marrow aspiration and biopsy showed hypercellularity with 
marked eosinophilia (77%) and erythroid differentiation series was 
hypocellular with normoblast maturation. The immunohistochemically 
of the bone biopsy was positive for myeloperoxidase and negative for 
CD34/CD99, consistent with CEL. Fluorescence in situ hybridization 
(FISH) for the beta-fraction of platelet-derived growth factor (PDGFRβ) 
and Philadelphia chromosome (Ph 1) were negative and the alfa PD-
GFR (Platelet-Derived Growth Factor) was positive and showed hetero-
zygosis in c.2531T>C on 18 Exon and homozygous in C.2562+1G>A at 
the region of the splicing site at the 18 intron. Treatment was initiated 
and maintained by administering 400mg/day imatinib mesylate. Labo-
ratory findings returned to normal ranges, with clinical improvement 
and a hematological response observed after the second month of 
therapy. Currently, the patient’s blood count shows the white blood 
cell count (5,400 total leukocytes), eosinophils (8.6/mm3), hemoglobin 
(15.5 g/dl), hematocrit (45.4%) and platelets (298,000/mm3) within 
normal ranges. The mutation search was negative in in peripheral 
blood one year after the initial treatment. Our work corroborates other 
studies on the efficacy of imatinib mesylate in the treatment of pa-
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Introduction
Blood and tissue eosinophilia is associated with se-
veral conditions. Elevation of eosinophil levels may 
have different origins, such as helminthic parasitic 
infection, inflammation, hypersensitive drug reac-
tion, adrenal insufficiency, and collagen diseases, 
in which cases the eosinophilia is classified as re-
active [1, 2, 3]. In reactive eosinophilia, the primary 
mechanism consists of an increase in interleukin 
production, especially that specific for eosinophil 
differentiation, interleukin-5 (IL-5).
Another cause of eosinophilia consists of a pri-
mary molecular failure involving hematopoietic stem 
cells and/or defects in signal transduction from 
eosinophilopoiesis-mediating receptors, which can 
cause clonal proliferation; these mechanisms under-
lie tumor-induced eosinophilia and in these cases 
eosinophilia is classified as a primary disease [4, 5].
Eosinophilia based hematological disorders, esta-
blished on the revised World Health Organization 
(WHO) classification in 2008, revised in 2016 [22], 
are divided into the following categories: Myeloid 
and lymphoid neoplasms with eosinophilia and rear-
rangement of the alpha platelet-derived growth fac-
tor receptor (PDGFRα), beta-platelet-derived growth 
factor receptor (PDGFRβ), or fibroblast growth fac-
tor receptor-1 (FGFR1) and provisional entity Mye-
loid/lymphoid neoplasms with PCM1-JAK2; Chronic 
Eosinophilic Leukemia (CEL) not otherwise specified 
(NOS) [6, 22].
Diagnostic evaluation of primary eosinophilia is 
based on a combination of morphological analysis 
of the blood and marrow, cytogenetic evaluation, 
fluorescence in situ hybridization, flow immunocy-
tometry, and evaluation of T cell clonally to detect 
histopathological or clonal evidence of an acute 
myeloid or lymphoproliferative disease or chronic. 
Screening for structural changes to primary eosino-
philia should begin with peripheral blood analysis 
for fusion of the FIP1L1-PDGFRα gene. The absen-
ce of FIP1L1-PDGFRα fusion should stimulate the 
evaluation of other primary eosinophilia associated 
with recurrent molecular abnormalities [7].
In the absence of the Philadelphia chromoso-
me, the rearrangement involving PDGFRα-FGFR1/
PDGFRβ/TEL, and no identification of other acute 
or chronic marrow neoplasias that present with eo-
sinophilia, we are facing a CEL NOS [7, 8]. Patients 
with mutations in the platelet-derived growth factor 
receptor (PDGFR) genes respond well to imatinib 
mesylate therapy [9]. This drug is a potent inhibitor 
of alpha and beta growth factors, which stimula-
te kinase activity [10]. These structural alterations 
tend to occur predominantly in men, between the 
second and fifth decade of life [11]. 
In view of the above, the objective of our stu-
dy was the diagnostic elucidation of a patient who 
was admitted with eosinophilic leukemia hypothesis 
to be clarified. Therefore, we report a case of pa-
cient with mutacion in gene PDGFR alfa exhibiting 
a satisfactory response to treatment with imatinib 
mesylate.
tients with CEL PDGFR alpha positive. We emphasize the importance 
of molecular studies, considering its relevance for the correct staging 
of the disease. Since CEL is a rare disease, it is important to define 
its etiology and anticipate its treatment, thus minimizing the damage 
induced by the disease. 
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Case report
A 25-year-old man was referred to the hematology 
service of Napoleão Laureano Hospital for diagnosis 
of a persistent cough and blood count alterations. 
Physical examination did not show adenomegaly or 
visceromegaly. On admission, the patient presented 
with a hemoglobin level of 12.5 g/dL, and a white 
blood cell count of 94,030/mm3, 68% of which 
were eosinophils. Data from laboratory monitoring 
of the patient, from the time of admission, are des-
cribed in Figure 1, 2. 
Laboratory assays testing for human lymphotrop-
ic T virus (HTLV), human immunodeficiency virus 
(HIV), Venereal Disease Research Laboratory (VDRL 
test), virus hepatitis C and B (HCV and HBsAg B), 
serum antigen antinuclear factor, C-reactive protein, 
anti-DNA antibody, and mucoprotein were negati-
ve. Protein electrophoresis exhibited a polyclonal hy-
pergammaglobulinemia pattern. Biochemical tests 
for kidney and liver functions revealed no changes; 
an echocardiogram revealed discrete right atrial 
hypertrophy. Computed tomography scans of the 
chest and abdomen were normal. Parasitic diseases 
were excluded by laboratory analysis and prophylac-
tic treatment.
The myelogram and bone marrow biopsy (BMB) 
showed hypercellular bone marrow with eosino-
philic proliferation, respectively, 73% and 95% im-
mature cells, and an absence of fibrosis, suggesting 
eosinophilic leukemia, as shown in Figure 3, A.
Figure 1:  Evolution of the patient’s white blood 
cell count during treatment with imati-
nib mesylate.
Source: Data collected by the authors.
Figure 2:  Evolution of the patient’s eosinophil per-
centage during treatment with imatinib 
mesylate.
Source: Data collected by the authors.
Figure 3:  A) Bone Marrow Biopsy (BMB): numerous 
eosinophils and bone marrow precursors.  
B) Immunohistochemistry: positive for 
myeloperoxidase. 
Source: Image captured by authors.
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The immunohistochemical study was positive for 
myeloperoxidase and negative for CD34/CD99, con-
sistent with eosinophilic leukemia, as shown in Figu-
re 3B. Bone marrow aspiration and biopsy showed 
hypercellularity with marked eosinophilia (77%). An 
erythroid differentiation series was hypocellular with 
normoblast maturation. Fluorescence in situ hybridi-
zation (FISH) for the beta-fraction of platelet-derived 
growth factor (PDGFRβ) and Philadelphia chromo-
some (Ph 1) were negative. 
Genetic analysis of PDGFR alpha was performed 
using the PCR-DNA technique, with material obtai-
ned from the bone marrow, followed by bidirec-
tional sequencing and analysis of exons 10, 12, 14 
and 18. The mutations identified were heterozygo-
sis in c.2531T>C on 18 exon and homozygous in 
C.2562+1G>A at the region of the splicing site at 
the 18 intron.
Treatment was initiated and maintained by ad-
ministering 400 mg/day imatinib mesylate. The 
patient became asymptomatic and the laboratory 
findings returned to normal ranges, with clinical 
improvement and a hematological response obser-
ved after the second month of therapy. Currently, 
the patient’s hemogram shows the white blood 
cell count (5,400 total leukocytes), eosinophils (8.6/
mm3), hemoglobin (15.5 g/dl), hematocrit (45.4%) 
and platelets (298,000/mm3) within normal ranges.
Discussion
Eosinophilia is defined when blood eosinophilia is 
greater than 1.5 × 109/L. There are several causes 
underlying HE, which can be divided into primary 
(clonal), secondary (reactive), hereditary (familial) 
and idiopathic [5, 12]. 
Under various conditions, eosinophils can produ-
ce and release a variety of biologically active subs-
tances that can invade target organs and cause 
dysfunction and/or damage. The harmful role of 
eosinophils results from their inflammatory, fibrotic, 
and thrombotic properties [12]. 
The diagnosis may be incidental due to labo-
ratory findings or clinical manifestations such as 
pruritus, constitutional symptoms, and symptoms 
related to multisystem injury [13]. Tissue infiltration 
occurs in several organs and systems, especially 
the heart, lungs, skin, central and peripheral ner-
vous system, and gastrointestinal tract. The main 
mechanism promoting injury is the release of cyto-
kines and the impact of the cytokines on several 
targets [4, 14]. 
While patients are commonly referred to the 
competent services with complaints of the respi-
ratory tract, heart disease is the leading cause of 
morbidity and mortality, occurring in up to 50% of 
cases [15]. Endomyocardial fibrosis progresses into 
restrictive cardiomyopathy, apart from the thicke-
ning and fibrosis of the atrioventricular valves, with 
valve regurgitation and formation of intracardiac 
thrombi [13, 14].
Specific therapies may potentially prevent mor-
bidity and mortality, if started early. When inves-
tigating cytogenetic causes involved in the etiolo-
gy of eosinophilia, the identification of PDGFRα or 
PDGFRβ rearrangements is critical because of the 
good response to treatment with imatinib mesylate 
[6]. Among the available therapies, imatinib mes-
ylate is consider the first choice in the treatment of 
CEL positive for when these mutations are positive 
[1, 9, 10, 12]. The drug is also used as therapy for 
the treatment of chronic myeloid leukemia and pa-
tients who are treated with the standard dose have 
favorable outcomes [16]. 
The first report of treatment with imatinib 
mesylate for Idiopathic Hypereosinophilia was in 
20 January 2017. Cases of hypereosinophilic syn-
drome patients were published, highlighting rapid 
and complete hematological responses to imatinib 
mesylate 100-400 mg per day [18, 19].
The identification of FIP1L1-PDGFRA transloca-
tion as a therapeutic target of this drug redefined 
such cases as a form of chronic eosinophilic leu-
kemia, WHO category of "Myeloid and lymphoid 
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neoplasms with eosinophilia and Abnormalities of 
PDGFRα, PDGFRβ or FGFR1 [17].
Cytogenetic differences have an impact on the 
response to treatment with imatinib mesylate when 
PDGFRA and PDGFRB are compared. The starting 
dose recommended by the FDA for patients with 
the FIP1L1-PDGFRA rearrangement is 100 mg per 
day. Cumulative data with long-term follow-up in-
dicate that this dose is sufficient to cause comple-
te and long-lasting hematological remissions. For 
patients with rearranged eosinophilia and PDGFRB 
myeloid neoplasms, the recommended dose is 400 
mg per day [7].
There have been reports of patients with CEL 
NOS or Hypereosinophilic Syndrome who bene-
fited from imatinib mesylate when given at doses 
higher than 400 mg per day [20]. In our patient, 
four months elapsed between the diagnosis and 
the start of treatment; complete hematologic res-
ponse occurred in the second month of treatment 
with a dosage of 400 mg/day, In agreement with 
the results found in the literature when referring to 
similar cases [21]. 
It is consensus in the literature on the satisfac-
tory response of CEL with PDGFRα ou PDGFRβ B e 
FGFR1 positive’s for mesylate imatinib [16, 17, 19]. 
Thus, our patient has been undergoing treatment 
for 25 months and is clinically and laboratory stably 
in outpatient follow-up.
Conclusion
In our study, the efficacy of imatinib mesylate in the 
treatment of patients with CEL PDGFR alpha posi-
tive, in which we were successful in the treatment 
was verified. We recommend molecular screening 
using the PCR technique for future studies and 
we consider it essential for the correct staging of 
our case, since the FISH technique did not allow 
the diagnostic elucidation of the case under study. 
We highlight that since CEL is a rare disease, it is 
important to define its etiology and anticipate its 
treatment, thus minimizing the damage induced by 
the disease. The main contribution of our work is 
because it is a rare form of CEL and is the first case 
of eosinophilic leukemia with mutations in the PD-
GFR alpha reported in northeastern Brazil.
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